Migraine Medications Safe in Pregnancy
For acute migraine treatment in pregnancy, use acetaminophen (paracetamol) as first-line therapy; if inadequate, add a triptan (particularly sumatriptan which has the most safety data), and consider NSAIDs only in the second trimester. 1, 2
Acute Treatment Algorithm
First-Line: Acetaminophen
- Acetaminophen is universally recommended as the safest first-line option throughout all trimesters 1, 2, 3
- Use adequate dosing without exceeding maximum daily limits
- If insufficient pain relief, escalate rather than continue inadequate treatment
Second-Line: Triptans
- Sumatriptan has the most robust pregnancy safety data and should be the preferred triptan if acetaminophen fails 4, 1, 3
- Recent evidence shows a better safety profile for triptans than previously believed 5
- Can be used sporadically throughout pregnancy when benefits outweigh risks 1
- Other triptans have less pregnancy data but are not contraindicated
Third-Line: NSAIDs (Trimester-Specific)
- Second trimester only: Ibuprofen can be used if acetaminophen and triptans are contraindicated or ineffective 1, 2
- Avoid in first trimester: Associated with increased miscarriage risk
- Contraindicated in third trimester: Risk of premature ductus arteriosus closure, oligohydramnios, and delayed labor 1, 2
Procedural Options
- Peripheral nerve blocks with lidocaine (greater occipital nerve blocks, supraorbital nerve blocks) have promising safety profiles and growing evidence 4, 6, 3
- These are particularly useful for severe, refractory migraine in pregnancy
Preventive Treatment (Use Only in Severe Cases)
When preventive therapy is absolutely necessary for severe, disabling migraine:
Acceptable Options:
- Low-dose propranolol (beta-blocker) - most commonly recommended despite limited quality evidence 4, 2
- Low-dose amitriptyline (tricyclic antidepressant) - use cautiously 2
Absolutely Contraindicated:
- Valproate/divalproex: Known teratogen with high risk of neural tube defects and developmental delays 4, 7
- Topiramate: Established teratogenic risk including oral clefts 4, 7
- Dihydroergotamine: Known teratogenic risk 4
Insufficient Safety Data (Avoid):
- CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) - no adequate human pregnancy data 4, 3
- Gepants (rimegepant, ubrogepant, zavegepant) - insufficient data 8, 4
- OnabotulinumtoxinA - emerging evidence but still limited 4
Critical Counseling Points
The 2025 ACP guidelines explicitly state: "In people of childbearing potential and in those who are pregnant or breastfeeding, discuss adverse effects of pharmacologic treatments during pregnancy and lactation" 9, 8
Common Pitfalls to Avoid:
- Do not leave disabling migraine untreated - untreated severe migraine poses risks to both mother and fetus 1, 3
- Do not use opioids or butalbital - explicitly not recommended even outside pregnancy, and recent data suggest particular hazards for butalbital-containing compounds in pregnancy 8, 5
- Do not assume all preventive medications are equally risky - some (valproate, topiramate) have definitive teratogenic risk while others (propranolol) have acceptable safety profiles 4, 7
Non-Pharmacological Approaches (Always First-Line)
Before and alongside any medication:
- Maintain hydration and regular meals
- Ensure adequate, consistent sleep
- Regular moderate-to-intense aerobic exercise
- Stress management with relaxation techniques or mindfulness
- Identify and avoid specific migraine triggers 9, 8, 3
Special Considerations
Women with migraine, particularly migraine with aura, have increased risk of pregnancy complications including preeclampsia, stroke, and preterm birth 5, 3. This necessitates closer monitoring but should not prevent appropriate migraine treatment.
Shared decision-making is essential given limited high-quality safety data for many medications, balancing maternal suffering against theoretical fetal risks 3.